--- title: "SL-325 Data Catalysts and Phase 2 Launch Plans Underpin Buy Rating on Shattuck Labs" type: "News" locale: "en" url: "https://longbridge.com/en/news/285637377.md" description: "TD Cowen analyst Marc Frahm has maintained a Buy rating on Shattuck Labs (STTK) stock, citing the promising profile of SL-325 and upcoming data catalysts. Key developments include the completion of Phase 1 study enrollment, with safety and pharmacokinetics data expected in Q2 2026, and a planned Phase 2 trial for Crohn’s disease in Q3 2026. Preclinical findings suggest a strong potential for DR3 blockade, supporting a multi-billion-dollar valuation. Needham also issued a Buy rating with a $14.00 price target." datetime: "2026-05-07T23:45:20.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285637377.md) - [en](https://longbridge.com/en/news/285637377.md) - [zh-HK](https://longbridge.com/zh-HK/news/285637377.md) --- # SL-325 Data Catalysts and Phase 2 Launch Plans Underpin Buy Rating on Shattuck Labs TD Cowen analyst Marc Frahm has maintained their bullish stance on STTK stock, giving a Buy rating today. ### Claim 55% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Marc Frahm has given his Buy rating due to a combination of factors, most notably the emerging profile of SL-325 and its upcoming data catalysts. He highlights that the Phase 1 healthy volunteer study has finished enrolling all single- and multiple-ascending-dose cohorts, with data on safety, pharmacokinetics and dynamics, receptor occupancy, and immunogenicity expected in the second quarter of 2026, which could validate strong target coverage with low anti-drug antibody formation. He also points to the planned launch of a randomized Phase 2 Crohn’s disease trial in the third quarter of 2026, with the possibility of an additional open-label Phase 2 study in another inflammatory indication that could broaden the opportunity. Combined with preclinical findings that suggest durable DR3 blockade and a potentially differentiated mechanism versus TL1A antibodies, as well as a cash position that supports near-term execution and the prospect of a multi-billion-dollar valuation if the profile is confirmed, these elements underpin his positive stance on Shattuck Labs’ shares. Frahm covers the Healthcare sector, focusing on stocks such as Incyte, Agios Pharma, and Revolution Medicines. According to TipRanks, Frahm has an average return of 22.6% and a 52.02% success rate on recommended stocks. In another report released today, Needham also maintained a Buy rating on the stock with a $14.00 price target. ### Related Stocks - [STTK.US](https://longbridge.com/en/quote/STTK.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [INCY.US](https://longbridge.com/en/quote/INCY.US.md) - [AGIO.US](https://longbridge.com/en/quote/AGIO.US.md) - [RVMD.US](https://longbridge.com/en/quote/RVMD.US.md) - [RVMDW.US](https://longbridge.com/en/quote/RVMDW.US.md) ## Related News & Research - [SciSparc: Subsidiary NeuroThera Labs Received Conditional Regulatory Approval for Acquisition of CliniQuantum | SPRC Stock News](https://longbridge.com/en/news/287920812.md) - [Aligos Therapeutics Presents Positive Data at the EASL Congress 2026 | ALGS Stock News](https://longbridge.com/en/news/287726278.md) - [Sobi to present new data on pegcetacoplan at ERA 2026](https://longbridge.com/en/news/288238139.md) - [Major Investor Makes Bold Move Into Artiva Biotherapeutics Stock](https://longbridge.com/en/news/287999515.md) - [Apogee eczema drugs gets Blackstone backing, heads to Phase 3](https://longbridge.com/en/news/287810590.md)